- Home
- ARTL vs OGEN Comparison
ARTL vs OGEN Comparison
Compare ARTL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- OGEN
- Stock Information
- Founded
- ARTL 2011
- OGEN 1996
- Country
- ARTL United States
- OGEN United States
- Employees
- ARTL N/A
- OGEN N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ARTL Health Care
- OGEN Health Care
- Exchange
- ARTL Nasdaq
- OGEN Nasdaq
- Market Cap
- ARTL 3.6M
- OGEN N/A
- IPO Year
- ARTL N/A
- OGEN N/A
- Fundamental
- Price
- ARTL $0.95
- OGEN $0.22
- Analyst Decision
- ARTL Strong Buy
- OGEN
- Analyst Count
- ARTL 2
- OGEN 0
- Target Price
- ARTL $5.50
- OGEN N/A
- AVG Volume (30 Days)
- ARTL 15.8K
- OGEN 353.7K
- Earning Date
- ARTL 03-03-2025
- OGEN 03-14-2025
- Dividend Yield
- ARTL N/A
- OGEN N/A
- EPS Growth
- ARTL N/A
- OGEN N/A
- EPS
- ARTL N/A
- OGEN N/A
- Revenue
- ARTL N/A
- OGEN N/A
- Revenue This Year
- ARTL N/A
- OGEN N/A
- Revenue Next Year
- ARTL N/A
- OGEN N/A
- P/E Ratio
- ARTL N/A
- OGEN N/A
- Revenue Growth
- ARTL N/A
- OGEN N/A
- 52 Week Low
- ARTL $0.91
- OGEN $0.21
- 52 Week High
- ARTL $1.60
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- ARTL 39.95
- OGEN 29.48
- Support Level
- ARTL $0.95
- OGEN $0.24
- Resistance Level
- ARTL $1.04
- OGEN $0.27
- Average True Range (ATR)
- ARTL 0.03
- OGEN 0.02
- MACD
- ARTL 0.01
- OGEN -0.00
- Stochastic Oscillator
- ARTL 36.51
- OGEN 5.09
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.